Exploration and Proof of Concept of the efficacy of combined treatment with ORY-1001 in oncological indications
For all these reasons, the general objectives pursued by this project are four:
- To demonstrate the safety and efficacy of the combined treatment of ORY-1001 with SOC treatments in a clinical setting, by conducting two Phase IIa trials of the Concept Test in patients with AML and SCLC.
- To improve the in vitro and in vivo models that allow to optimize in the same experimental model the evaluation of drugs with diverse mechanisms of action and directed to the treatment of cancer, and to explore in them new possible synergistic combinations with the ORY- 1001.
- To validate the use of two preselected biomarkers for the stratification of SCLC patients as predictive markers of response to ORY-1001.
- To identify and characterize new pharmacodynamic biomarkers useful for the stratification and / or monitorization of patients, predictors of the progression of the pathology and / or response to treatment, etc.
Project Budget: 1.500.458,20 €
LEITAT Budget: 171.681,20 €
Financial Framework: RTC
Contract number: RTC-2017-6407-1
Start Date: 01/01/2018
End Date: 31/12/2020
The project COMBOEPOC, with file number RTC-2017-6407-1, approved in the 2017 Call for the State Program of R+D+i, oriented to the Challenges of the Society, has been financed by the Ministry of Economy, Industry and Competitiveness and co-financed through European Union FEDER funds with the main objective of Promoting technological development, innovation and quality research.